SEC For	m 4																	
	FORM	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549													OMB APPROVAL			
Check Section obligat Instruc	STATEMENT OF CHANGES IN BENEFICIAL OWNER Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940											Estimated average burden						
1. Name and Address of Reporting Person* CHURCH KEVIN					Athira Pharma, Inc. [ ATHA ]									Officer (give title Othe			on(s) to Issu 10% Ow Other (s	ner
(Last) (First) (Middle) C/O ATHIRA PHARMA, INC. 18706 NORTH CREEK PARKWAY, SUITE 1(				04		3. Date of Earliest Transaction (Month/Day/Year) 01/18/2022									X Oncer (give the below) below) Executive VP, Research			
(Street) BOTHELL WA 98011					_ 4.										up Filing (Check Applicable ne Reporting Person ore than One Reporting			
(City)	(S	i. ratio	ative Securities Acquired, Disposed of, or Benefic								v Owned							
1. Title of Security (Instr. 3) 2. Transat Date (Month/Date)				action	n 2 ear) i	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.		4. Securities Acquired (A)		d (A) or	or 5. Amount		Form (D) or	m: Direct or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			
Common Stock <sup>(1)</sup> 11/18/					8/202	2021 (2)		Α	v	96	Α	\$12.51				D		
			Table II -								oosed of converti			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	4. Transa Code (l 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date E Expiratic (Month/E	on Da		e of Securit		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	e s dly g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	ble	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	5/1(3)		
Stock Option (Right to Buy)	\$10.64	01/18/2022			A		100,000		(4)		01/17/2032	Common Stock	100,000	\$0.00	100,00	00	D	

## Explanation of Responses:

1. The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2021 through November 18, 2021. This transaction is also exempt under Rule 16b-3(c).

2. The Purchase Period ended November 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 18, 2021.

3. In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2021.

4. One forty-eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter.

## **Remarks:**

## /s/ Glenna Mileson, Attorney-

in-fact on behalf of Kevin 01/20/2022 Church

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.